Perioperative management of direct oral anticoagulants in urological surgery

Perioperative management of direct oral anticoagulants in urological surgery - PAUSE URO

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00033173

Enrollment

476

Registered

2023-12-19

Start date

2023-12-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All urological patients on DOACs undergoing elective surgical intervention

Interventions

Group 1: PAUSE-URO-Protocol (Perioperative pause of direct oral anticoagulants using a standardised protocoll)

Eligibility

Sex/Gender

All

Age

18 Years to 95 Years

Inclusion criteria

Inclusion criteria: - Patient age = 18 years (with atrial fibrillation, history of deep vein thrombosis, and left atrial enlargement). - Long-term therapy with a direct oral anticoagulant (Rivaroxaban, Apixaban, Dabigatran, or Edoxaban). - Elective urological operation.

Exclusion criteria

Exclusion criteria: - Mechanical heart valve and/or use of vitamin K antagonists. - Patients with GFR (glomerular filtration rate) < 30 ml/min (Dabigatran). - Patients with GFR < 15 ml/min (Apixaban, Rivaroxaban). - Ongoing dual antiplatelet therapy (ADP receptor blocker, P2Y12). - Patients planned for cystectomy with urinary diversion. - Cognitive limitations or psychiatric conditions preventing adherence to the study protocol.

Design outcomes

Primary

Measure	Time frame
Major Bleeding Events	—

Secondary

Measure	Time frame
Secondary Endpoints: - minor bleeding bleeding events - mortality - thromboembolic Events - Non-adherence to study protocoll	—

Countries

Germany

Contacts

Public ContactKarl-Friedrich Kowalewski

Klinik für Urologie und Urochirurgie

karl-friedrich.kowalewski@umm.de+49 621 383 2235

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026